Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)

Study acronym: GECOP-MMC
StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jan 2027 to Oct 2029
    • Study sites: 30 to 31
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2022 to Mar 2, 2022
    • Site details revised at 30 of 30 sites
    • Publications: details revised at 1 of 1 entry
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or without (Group 2) HIPEC with Mitomycin-C.
Trial Details
NCT Number NCT05250648
Lead Sponsor Hospital Universitario de Fuenlabrada
Collaborators: Instituto de Investigación Hospital Universitario La Paz
Conditions
(from sponsor)		 Peritoneal Carcinomatosis, Colon Cancer
Related terms Colonic Neoplasms, Peritoneal Neoplasms
Enrollment 216 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov